US20170071248A1 - System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations - Google Patents

System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations Download PDF

Info

Publication number
US20170071248A1
US20170071248A1 US14/856,116 US201514856116A US2017071248A1 US 20170071248 A1 US20170071248 A1 US 20170071248A1 US 201514856116 A US201514856116 A US 201514856116A US 2017071248 A1 US2017071248 A1 US 2017071248A1
Authority
US
United States
Prior art keywords
nicotine
formulation
particles
micron
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/856,116
Other languages
English (en)
Inventor
Alex Stenzler
Noe Zamel
Arthur Slutsky
Steven Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nico Puff Corp
Philip Morris Products SA
Original Assignee
Sansa Corp Barbados Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/856,116 priority Critical patent/US20170071248A1/en
Application filed by Sansa Corp Barbados Inc filed Critical Sansa Corp Barbados Inc
Priority to CN201510717020.5A priority patent/CN106539122B/zh
Priority to KR1020187007522A priority patent/KR102710989B1/ko
Priority to MX2018003288A priority patent/MX2018003288A/es
Priority to RU2018113274A priority patent/RU2707104C2/ru
Priority to PCT/US2016/051959 priority patent/WO2017048970A1/fr
Priority to CA2998858A priority patent/CA2998858A1/fr
Priority to EP16847311.4A priority patent/EP3349738A4/fr
Priority to JP2018514439A priority patent/JP7021078B2/ja
Publication of US20170071248A1 publication Critical patent/US20170071248A1/en
Assigned to SANSA CORPORATION (BARBADOS) INC. reassignment SANSA CORPORATION (BARBADOS) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAN, STEVE
Assigned to SANSA CORPORATION (BARBADOS) INC. reassignment SANSA CORPORATION (BARBADOS) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STENZLER, ALEX
Assigned to SANSA CORPORATION (BARBADOS) INC. reassignment SANSA CORPORATION (BARBADOS) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SLUTSKY, ARTHUR
Assigned to SANSA CORPORATION (BARBADOS) INC. reassignment SANSA CORPORATION (BARBADOS) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELLIS, STEVEN
Assigned to SANSA CORPORATION (BARBADOS) INC. reassignment SANSA CORPORATION (BARBADOS) INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZAMEL, NOE
Priority to IL258138A priority patent/IL258138A/en
Priority to US16/521,913 priority patent/US11707432B2/en
Assigned to NICO PUFF CORPORATION reassignment NICO PUFF CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SANSA CORPORATION
Assigned to PHILIP MORRIS PRODUCTS S.A. reassignment PHILIP MORRIS PRODUCTS S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NICO PUFF CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/80—Testing
    • A24F47/002—
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/50—Control or monitoring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Definitions

  • inhaled cigarette smoke causes airway irritation and cough, due largely to the fact that nicotine is one of the most common inhaled irritants to the human respiratory tract. This irritation results in a sensation of harshness when nicotine is inhaled by a subject.
  • a subject may develop a degree of tolerance to the harshness experienced. Accordingly, the level of harshness tolerated, or preferred, during nicotine inhalation can be very different from one subject to the next.
  • a method of controlling the harshness of inhaled nicotine comprises the steps of identifying a concentration of nicotine for a subject to inhale to achieve a desired level of harshness per inhalation, identifying the total dose of nicotine to be inhaled by the subject, and providing the subject with an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, such that the total amount of nicotine particles in the formulation equals the total dose of nicotine.
  • the nicotine particles used comprise at least one nicotine salt.
  • the at least one nicotine salt is nicotine tartrate.
  • the nicotine particles further comprise at least one sugar.
  • the at least one sugar is lactose.
  • the nicotine particles are substantially between 2-5 micron in size.
  • the concentration of nicotine is about 1.5% to about 20%.
  • the formulation further comprises a stabilizing agent. In one embodiment the formulation is inhaled using an inhaler.
  • the method includes the steps of identifying a concentration of nicotine in a nicotine formulation for a subject to inhale to achieve a desired level of harshness per inhalation, providing a first dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, and providing at least one additional dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, wherein the amount of the formulation in the at least one additional dose is less than the amount of the formulation in the first dose.
  • the total dose of nicotine is decreased per dose, while the harshness of the administered doses remains substantially constant.
  • the method includes the steps of identifying a concentration of nicotine in a nicotine formulation for a subject to inhale to achieve a desired level of harshness per inhalation, providing a first dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, providing at least one additional dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, wherein the amount of the formulation in the at least one additional dose is less than the amount of the formulation in the first dose, and providing at least one additional dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, wherein the amount of the formulation in the at least one additional dose is less than the amount of the formulation in the first dose.
  • kits for controlling the harshness of inhaled nicotine comprising at least an amount of a nicotine formulation comprising nicotine particles, and an instruction material for the use therewith.
  • the kit comprises a dry powder inhaler.
  • a dry powder nicotine formulation suitable for inhalation comprising nicotine particles, wherein the nicotine particles are substantially between about 1-10 micron in size.
  • the nicotine particles are substantially between about 2-5 micron in size.
  • less than about 10% of the nicotine particles are less than about 1 micron in size.
  • less than about 10% of the nicotine particles are less than about 2 micron in size.
  • at least about 90% of the nicotine particles are less than about 10 micron in size.
  • at least about 90% of the nicotine particles are less than about 5 micron in size.
  • less than about 10% of the nicotine particles are less than about 1 micron in size and wherein at least about 90% of the nicotine particles are less than about 10 micron in size.
  • less than about 10% of the nicotine particles are less than about 2 micron in size and wherein at least about 90% of the nicotine particles are less than about 5 micron in size.
  • the formulation includes a nicotine based component having particles substantially between about 1-10 micron in size, and a cough suppressant component having particles substantially between about 5-10 micron in size.
  • the cough suppressant component comprises menthol or mint.
  • the nicotine based component particles are substantially between about 2-5 micron in size and the cough suppressant component particles are substantially between about 5-8 micron in size.
  • the formulation further includes a cough suppressant component having particles substantially between about 10-200 micron in size.
  • the cough suppressant component having particles substantially between about 10-200 micron in size comprises menthol or mint.
  • the formulation includes a flavor component having particles substantially between about 10-1000 micron in size.
  • the flavor component comprises menthol or mint.
  • FIG. 1 is a chart depicting exemplary preparations for achieving various levels of harshness by adjusting one or both of the total amount of powder formulation and the concentration of nicotine in the powder formulation, while maintaining constant the total dose of nicotine delivered within the amount of powder formulation.
  • FIG. 2 is a chart depicting exemplary preparations for achieving decreasing total doses of nicotine delivered within the amount of powder formulation, by adjusting the total amount of powder formulation containing nicotine particles to maintain a substantially constant level of harshness across the variable doses of nicotine.
  • FIG. 3 is a chart depicting exemplary preparations for achieving decreasing total doses of nicotine delivered within the amount of powder formulation, by adjusting the total amount of powder formulation containing nicotine particles to increase the level of harshness across the variable doses of nicotine.
  • FIG. 4 is a flowchart of an exemplary method of controlling the harshness of nicotine inhaled by a subject.
  • FIG. 5 is a flowchart of an exemplary method for delivering reduced dosages of nicotine to a subject over a number of doses, while maintaining a substantially constant level of harshness per inhalation for each dose.
  • FIG. 6 is a flowchart of an exemplary method for delivering reduced dosages of nicotine to a subject over a number of doses, while increasing the level of harshness per inhalation for each dose.
  • FIG. 7 is a flowchart depicting an exemplary method of manufacturing a formulation of the present invention comprising dry mixing.
  • FIG. 8 is a flowchart depicting an exemplary method of manufacturing a formulation of the present invention comprising wet mixing.
  • an element means one element or more than one element.
  • “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
  • nicotine dose and “total nicotine dose” refer to the total amount of nicotine to be delivered to a subject in order to achieve a target nicotine blood concentration.
  • formulation amount refers to the total amount of a dry powder formulation packed in a disposable container, such as a capsule or blister pack, to be used with a dry powder inhaler, or to the total amount of a bulk dry powder formulation that can be loaded into a delivery chamber or compartment of a dry powder inhaler.
  • the term also refers to the total amount of a dry powder formulation containing a nicotine dose to be delivered to a subject in order to achieve a particular blood nicotine concentration. Accordingly, the formulation amount includes the total dose of nicotine and may further include any additional pharmaceutically acceptable material, composition or carrier.
  • the term “harshness” refers to the sensation or perception of irritation in a subject's airways after inhaling nicotine particles.
  • inhalation refers to the single act of inhaling an amount of a nicotine dry powder formulation, typically from a dry powder inhaler.
  • duration of an inhalation can be limited either by the control of the subject over the inhaler, such as by the physical act of continuously inhaling for a period of time and then stopping, or by a physical attribute of the inhaler.
  • the described size or size range of a particle should be considered as the mass median aerodynamic diameter (MMAD) of the particle or set of particles.
  • MMAD mass median aerodynamic diameter
  • Such values are based on the distribution of the aerodynamic particle diameters defined as the diameter of a sphere with a density of 1 gm/cm 3 that has the same aerodynamic behavior as the particle which is being characterized. Because the particles described herein may be in a variety of densities and shapes, the size of the particles is expressed as the MMAD and not the actual diameter of the particles.
  • pharmaceutically acceptable refers to those properties and/or substances that are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
  • “Pharmaceutically acceptable” may also refer to a carrier, meaning a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.
  • carrier meaning a medium that does not interfere with the effectiveness of the biological activity of the active ingredient(s) and is not toxic to the host to which it is administered.
  • Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, Pa.), which is incorporated herein by reference.
  • composition refers to a mixture of at least one compound or molecule useful within the invention with one or more different compound, molecule, or material.
  • an “instructional material” includes a physical or electronic publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition and method of the invention for its designated use.
  • the instructional material of the kit of the invention may, for example, be affixed to a container which contains the composition or be shipped together with a container which contains the composition. Alternatively, the instructional material may be delivered separately from the container with the intention that the instructional material and the composition be used cooperatively by the recipient.
  • ranges throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
  • nicotine blood levels are ultimately controlled by the total dose of inhaled nicotine delivered to the airways of a subject in a specified formulation, and the harshness of the formulation is determined solely by the characteristics of the nicotine.
  • the harshness experienced by the subject during any single inhalation is fixed, meaning the level of harshness cannot be increased or decreased without discontinuing, or improperly administering, the dose. This significantly limits the user experience associated with an inhaled nicotine product.
  • a total dose of nicotine necessary for achieving a specified nicotine blood level can instead be formulated into powder doses having various concentrations within various total formulation amounts.
  • a formulation powder of low nicotine concentration will result in a low level of harshness during inhalation, and may be delivered in a relatively larger total amount of powder in order to achieve the desired blood nicotine level.
  • a formulation powder of high nicotine concentration will result in a high level of harshness during inhalation, but can be delivered in a relatively smaller amount of powder in order to achieve the desired blood nicotine level.
  • the harshness experienced by a subject when inhaling a nicotine-based dry powder formulation can be altered by changing one or both of: 1) the total powder formulation amount, and 2) the concentration of nicotine within the total powder formulation amount.
  • dry powder inhalers designed specifically for delivering a powder formulation dose across multiple inhalations may be used. Examples of such dry powder inhalers can be found in co-owned U.S. Patent Application Ser. Nos. 62/147,798; 62/147,803; 62/147,806; 62/147,808; and 62/148,030, the entire disclosures of which are each incorporated by reference herein in their entirety.
  • the dry powder formulation may be placed in a sealed storage chamber, such as a capsule or a blister pack, which can be loaded into any of the devices described in the aforementioned, co-owned patent applications.
  • each formulation is designed to deliver the same total dose of nicotine (1 mg).
  • the total dose of nicotine forms part of a 10 mg total formulation amount of powder, which results in a nicotine concentration of 10% in the formulation amount. Assuming that approximately 1 mg of powder can be inhaled per inhalation, this means that about 0.10 mg of nicotine is inhaled per inhalation, and the total dose of nicotine is administered after completion of about 10 inhalations to take up the 10 mg of formulation powder.
  • the total dose of nicotine forms part of a 20 mg total formulation amount of powder, which results in a nicotine concentration of 5% in the formulation amount.
  • the total dose of nicotine forms part of a 5 mg total formulation amount of powder, which results in a nicotine concentration of 20% in the formulation amount.
  • the nicotine formulation can be uniquely designed to achieve a specific level of harshness suitable for use with any subject, no matter what tolerance to harshness or irritant a subject may have.
  • the nicotine powder formulation may be specifically tailored and administered to more accurately mimic the harshness experienced by a subject when smoking For example, if a subject is being treated with a smoking cessation therapy, the total dose of nicotine can be gradually reduced while maintaining the harshness experienced throughout the process.
  • FIG. 2 three different formulations are outlined, where each formulation is designed to deliver a different (smaller) total dose of nicotine. Starting with Formulation 4, assume that the targeted level of harshness is achieved by inhalation of 0.1 mg of nicotine per inhalation.
  • 1 mg total dose of nicotine must form part of a 10 mg total formulation amount of powder, which results in a nicotine concentration of 10% in the formulation amount. Assuming that approximately 1 mg of powder can be inhaled per inhalation, this means that about 0.10 mg of nicotine is inhaled per inhalation, and the total dose of nicotine is administered after completion of about 10 inhalations at the desired level of harshness.
  • Formulation 5 is designed for delivery of a total dose of 0.8 mg of nicotine. Accordingly, 0.8 mg total dose of nicotine must form part of an 8 mg total formulation amount of powder, which again results in a nicotine concentration of 10% in the formulation amount.
  • Formulation 6 is designed for delivery of a total dose of 0.6 mg of nicotine. Accordingly, 0.6 mg total dose of nicotine must form part of a 6 mg total formulation amount of powder, which again results in a nicotine concentration of 10% in the formulation amount.
  • the total dose of nicotine can be gradually reduced while also altering the harshness experienced.
  • FIG. 3 three different formulations are outlined, where each formulation is designed to deliver a different (smaller) total dose of nicotine with slightly increased levels of harshness experienced.
  • Formulation 7 assume that the initial level of harshness is achieved by inhalation of 0.1 mg of nicotine per inhalation. Accordingly, 1 mg total dose of nicotine must form part of a 10 mg total formulation amount of powder, which results in a nicotine concentration of 10% in the formulation amount.
  • Formulation 8 is designed for delivery of a total dose of 0.8 mg of nicotine with slightly increased harshness. Accordingly, 0.8 mg total dose of nicotine may form part of a 7 mg total formulation amount of powder, which results in a nicotine concentration of about 11.4% in the formulation amount.
  • Formulation 9 is designed for delivery of a total dose of 0.6 mg of nicotine with again slightly increased harshness. Accordingly, 0.6 mg total dose of nicotine may form part of a 5 mg total formulation amount of powder, which results in a nicotine concentration of about 12% in the formulation amount.
  • the present invention may include methods for controlling the harshness of nicotine inhaled by a subject, including increasing, decreasing or maintaining the harshness of a nicotine powder formulation inhaled by a subject.
  • method 400 includes the steps of identifying a concentration of nicotine for a subject to inhale to achieve a desired level of harshness per inhalation 410 , identifying the total dose of nicotine to be inhaled by the subject 420 , and providing the subject with an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, such that the total amount of nicotine particles in the formulation equals the total dose of nicotine 430 .
  • method 500 may be used for delivering reduced dosages of nicotine to a subject over a number of doses, while maintaining a substantially constant level of harshness per inhalation for each dose.
  • Method 500 may include the steps of identifying a concentration of nicotine in a nicotine formulation for a subject to inhale to achieve a desired level of harshness per inhalation 510 , providing a first dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine 520 , and providing at least one additional dose comprising an amount of a formulation comprising nicotine particles having the identified concentration of nicotine, wherein the amount of the formulation in the at least one additional dose is less than the amount of the formulation in the first dose 530 .
  • method 600 may be used for delivering reduced dosages of nicotine to a subject over a number of doses, while increasing the level of harshness per inhalation for each dose.
  • Method 600 may include the steps of identifying a first concentration of nicotine in a nicotine formulation for a subject to inhale to achieve a first level of harshness per inhalation 610 , identifying at least one additional concentration of nicotine in a nicotine formulation for a subject to inhale to achieve a level of harshness per inhalation that is greater than the level of harshness achieved via the first concentration of nicotine 620 , providing a first dose comprising an amount of a formulation comprising nicotine particles having the identified first concentration of nicotine 630 , and providing at least one additional dose comprising an amount of a formulation comprising nicotine particles having the identified additional concentration of nicotine, wherein the amount of the formulation in the at least one additional dose is less than the amount of the formulation in the first dose 640 .
  • any manner of increasing, decreasing or maintaining the total dose of nicotine in a nicotine formulation can be combined with any manner of increasing, decreasing or maintaining the level of harshness experienced by the subject inhaling the nicotine formulation.
  • the present invention relates to the ability to alter one or both of these parameters when delivering a total dose of nicotine to a subject via a dry powder inhaler.
  • the actual amount of powder inhaled per inhalation can be dependent on the functionality of the dry powder inhaler used, or it can be user performance dependent, where a user elects to take a shallower, or deeper, inhalation through the dry powder inhaler used.
  • the subject can more consistently insure uptake of the total dose of nicotine, as any user error occurring during a single inhalation is ultimately corrected through one or more subsequent inhalations.
  • a nicotine therapy course may last a number of days. In one embodiment, the course of nicotine therapy lasts between about 7 days, to about 30 days. In another embodiment, the course of nicotine therapy lasts between about 10 days, to about 45 days. In another embodiment, the course of nicotine therapy lasts between about 15 days, to about 60 days. In another embodiment, the course of nicotine therapy lasts between about 30 days, to about 90 days. In a preferred embodiment, the course of nicotine therapy lasts about 30 days. In another preferred embodiment, the course of nicotine therapy lasts about 45 days. In another preferred embodiment, the course of nicotine therapy lasts about 60 days. In another preferred embodiment, the course of nicotine therapy lasts about 90 days.
  • the present invention may further include a set of instructions for using or electing a particular nicotine-based powder formulation to achieve a desired level of harshness upon inhalation.
  • the set of instructions may be conveyed to the subject in the form of an “instruction material,” such as a pamphlet, manual, or any electronic file format, such as an email, web page, SMS or the like, which can further be part of a kit or associated therewith.
  • the present invention may further include a nicotine therapy kit, including, but not limited to, smoke cessation kits.
  • the kit may include a plurality of nicotine-based powder formulation doses contained in a sealed storage chamber, such as a capsule or a blister pack.
  • a sealed storage chamber such as a capsule or a blister pack.
  • at least two of the formulation doses have equal amounts of a total nicotine, but at different nicotine concentrations.
  • the kit comprises at least two sets of bulk nicotine-based powder having different concentrations of nicotine, and means for measuring set amounts of the powders, such as a scoop or a graduated measuring container, that can be loaded into the storage chamber of a dry powder inhaler.
  • the kit comprises a dry powder inhaler with one or more reservoirs or other compartments suitable for holding one or more bulk nicotine-based powder formulations, and further may optionally include a metering mechanism for dispensing or loading a designated amount of formulation for inhalation.
  • the kit includes pre-filled powder capsules for a set course of nicotine therapy or treatment, such as for example a 30 day course of treatment.
  • the capsules can be filed with various amounts of powder of various nicotine concentrations, to achieve variable levels of harshness while delivering the same total nicotine dose per the therapy regimen.
  • the kit includes instructional materials which describe the steps for a method for nicotine therapy, including, but not limited to, smoke cessation therapy.
  • the steps of the method can include a starting dose, regular doses thereafter, such as multiple daily doses for example, and a final dose, to be administered by means of loading the dry powder formulation doses into a dry powder inhaler.
  • the instruction material may also include steps for modulating or electing the harshness of inhalation for any particular administered dosage, such that the subject of the therapy may select the level of harshness experienced by administering the sealed formulation dose corresponding to the level of harshness desired.
  • the instruction material may instruct the user on a set number of days course of nicotine therapy, in which the daily nicotine dose may be modulated, while the harshness of the administered doses remains about the same.
  • the course of nicotine therapy lasts between about 7 days, to about 30 days.
  • the course of nicotine therapy lasts between about 10 days, to about 45 days.
  • the course of nicotine therapy lasts between about 15 days, to about 60 days.
  • the course of nicotine therapy lasts between about 30 days, to about 90 days.
  • the course of nicotine therapy lasts about 30 days.
  • the course of nicotine therapy lasts about 45 days.
  • the course of nicotine therapy lasts about 60 days.
  • the course of nicotine therapy lasts about 90 days.
  • the daily nicotine dose is increased daily, while the harshness of the administered doses remains about the same.
  • the daily nicotine dose is increased daily for a period of time, then decreased daily for a period of time, while the harshness of the administered doses remains about the same.
  • the daily nicotine dose is decreased daily, while the harshness of the administered doses remains about the same.
  • the present invention provides compositions and methods related to a dry powder nicotine formulation suitable for inhalation.
  • the formulation is comprised of nicotine particles and at least one sugar.
  • the nicotine particles are comprised of a nicotine salt.
  • the present invention also provides methods for producing formulations of the invention.
  • the present invention relates to dry powder formulations of nicotine, and optionally other selected materials, wherein the nicotine component and optional additional components fall within controlled particle size ranges.
  • the formulation includes nicotine particles (also referred to herein as the nicotine-based component) sized substantially between about 1-10 microns, based on the MMAD of the particles.
  • the formulation includes nicotine particles sized substantially between about 1-7 microns.
  • the formulation includes nicotine particles sized substantially between about 2-5 microns.
  • the formulation includes nicotine particles sized substantially between about 2-3 microns.
  • the formulations of the present invention remove or at least reduce a subject's ability to exhale nicotine back into the environment, thereby effectively reducing or removing the production of the nicotine contained in second hand smoke. Further, by selectively limiting or excluding non-respirable nicotine particles, the formulations of the present invention reduce unwanted irritation caused by nicotine particles trapped in the larger airways, oro-pharynx, the glottis vocal cords and other anatomic regions more proximal or closer to the mouth.
  • the smallest particles within the nicotine particle size range are at least about 1 micron, at least about 1.1 microns, at least about 1.2 micron, at least about 1.3 micron, at least about 1.4 micron, at least about 1.5 micron, at least about 1.6 micron, at least about 1.7 micron, at least about 1.8 micron, at least about 1.9 micron, or at least about 2 micron.
  • the largest particles within the nicotine particle size range are no greater than about 10 micron, no greater than about 7 micron, no greater than about 6 micron, no greater than about 5 micron, no greater than about 4.5 micron, no greater than about 4 micron, no greater than about 3.5 micron, or no greater than about 3 micron.
  • no more than about 10% of the nicotine particles are less than about 1 micron. In certain embodiments, no more than about 10% of the nicotine particles are less than about 2 micron. In other embodiments, at least 90% of the nicotine particles are less than about 10 micron. In other embodiments, at least 90% of the nicotine particles are less than about 7 micron. In other embodiments, at least 90% of the nicotine particles are less than about 5 micron. In one embodiment, no more than about 10% of the nicotine particles are less than about 1 micron and at least 90% of the nicotine particles are less than about 10 micron. In one embodiment, no more than about 10% of the nicotine particles are less than about 1 micron and at least 90% of the nicotine particles are less than about 7 micron.
  • no more than about 10% of the nicotine particles are less than about 2 micron and at least 90% of the nicotine particles are less than about 5 micron. In one embodiment, no more than about 10% of the nicotine particles are less than about 2 micron and at least 90% of the nicotine particles are less than about 3 micron.
  • the particle size ranges described herein are not absolute ranges.
  • a nicotine particle mixture of the present invention with a size range of about 2-5 microns can contain a portion of particles that are smaller or larger than the about 2-5 micron range.
  • the particle size value as presented for any particular component of the formulations of the present invention represents a D90 value, wherein 90% of the particles sizes of the mixture are less than the D90 value.
  • the particle size range represents a particles size distribution (PSD) wherein a percentage of the particles of the mixture lie within the listed range.
  • PSD particles size distribution
  • a nicotine particle size range of about 2-5 microns can represent a mixture of nicotine particles having at least 50% of the particles in the range of about 2-5 microns, but more preferably a higher percentage, such as, but not limited to: 60%, 70%, 80%, 90%, 95%, 97%, 98% or even 99%.
  • the formulation of the present invention may optionally include a cough suppressant component having particles sized substantially between 5 and 10 microns.
  • the cough suppressant component is menthol or mint.
  • the cough suppressant component may include benzocaine. It should be appreciated that the cough suppressant component can include any compound approved for suppressing cough. By selectively including menthol or mint particles between 5-10 microns, these non-respirable menthol or mint particles can reduce cough by soothing irritation in the subject's upper airways. Accordingly, in some embodiments, the smallest particles within the cough suppressant component particle size range are at least about 5 micron, at least about 6 micron, at least about 7 micron, or at least about 8 micron.
  • the largest particles within the cough suppressant component particle size range are no greater than about 10 micron, no greater than about 9 micron, no greater than about 8 micron, or no greater than about 7 micron. In certain embodiments, no more than about 10% of the cough suppressant particles are less than about 5 micron. In other embodiments, at least 90% of the cough suppressant particles are less than about 10 micron. In other embodiments, at least 90% of the cough suppressant particles are less than about 8 micron. In one embodiment, no more than about 10% of the cough suppressant particles are less than 4 micron and at least 90% of the cough suppressant particles are less than about 10 micron.
  • the cough suppressant component is composed of particles substantially in the range of 5-10 micron, the cough suppressant component can comprise particles in a broader range. In one embodiment, the cough suppressant component can comprise particles in the range of 5-25 micron. In another embodiment, the cough suppressant component comprises particles substantially in the range of 5-50 micron. In yet another embodiment, the cough suppressant component comprises particles substantially in the range of 5-100 micron.
  • the formulation of the present invention may optionally include a cough suppressant component having particles sized substantially between 10-200 microns.
  • This cough suppressant component can be added to the formulation instead of, or in addition to, the cough suppressant component in the range of 5-10 previously discussed.
  • the formulation of the present invention can comprise two cough suppressant components, wherein each cough suppressant component has a substantially different particle size distribution.
  • the 10-200 micron cough suppressant component may reduce a cough caused by irritation of the oro-pharynx, the glottis vocal cords and other anatomic regions more proximal or closer to the mouth that contain receptors that can trigger cough or trigger other unwanted sensations. As contemplated herein, these larger particles are substantially prohibited from entering the sub-glottic airways.
  • the smallest particles within the cough suppressant component particle size range are at least about 10 micron, at least about 12 micron, at least about 20 micron, at least about 30 micron, or at least about 50 micron.
  • the largest particles within the cough suppressant component particle size range are no greater than about 200 micron, no greater than about 150 micron, no greater than about 120 micron, no greater than about 100 micron, no greater than about 90 micron, or no greater than about 80 micron.
  • no more than about 10% of the cough suppressant component particles are less than about 10 micron. In certain embodiments, no more than about 10% of the cough suppressant component particles are less than about 20 micron.
  • the cough suppressant component particles are less than about 200 micron. In other embodiments, at least 90% of the cough suppressant component particles are less than about 150 micron. In other embodiments, at least 90% of the cough suppressant component particles are less than about 100 micron. In one embodiment, no more than about 10% of the cough suppressant component particles are less than 10 micron and at least 90% of the cough suppressant component particles are less than about 200 micron. In one embodiment, no more than about 10% of the cough suppressant component particles are less than about 12 micron and at least 90% of the cough suppressant component particles are less than about 100 micron. In one embodiment, the cough suppressant component includes menthol or mint particles between about 10-200 microns in size, which may provide a soothing effect in areas of particle impact.
  • the cough suppressant component having particles between about 10-200 microns in size may include benzocaine. It should be appreciated that the cough suppressant component having particles between about 10-200 microns in size can include any compound approved for suppressing cough.
  • the addition of at least one component in the formulation of the present invention other than the nicotine component may act to dilute the nicotine containing particles and decrease cough caused by nicotine irritating the oro-pharynx, vocal cords and other anatomic regions proximal to the trachea.
  • the formulation of the present invention may optionally include a flavor component having particles sized substantially between about 10-1000 microns.
  • the flavor component is composed of particles substantially in the range of about 10-200 micron.
  • the flavor component is composed of particles substantially in the range of about 10-100 micron. This flavor component utilizes such embedded larger particles that may impact the subject in the oral cavity to produce a desired flavor. Further, by limiting such flavor component particles to larger than about 10 microns in size, these particles are limited in their ability to enter into the subject's lungs.
  • the smallest particles within the flavoring component particle size range are at least about 10 micron, at least about 12 micron, at least about 20 micron, at least about 30 micron, or at least about 50 micron.
  • the largest particles within the flavoring component particle size range are no greater than about 1000 micron, no greater than about 500 micron, no greater than about 200 micron, no greater than about 150 micron, no greater than about 120 micron, no greater than about 100 micron, no greater than about 90 micron, or no greater than about 80 micron.
  • no more than about 10% of the flavor component particles are less than about 10 micron. In certain embodiments, no more than about 10% of the flavor component particles are less than about 20 micron.
  • At least 90% of the flavor component particles are less than about 1000 micron. In other embodiments, at least 90% of the flavor component particles are less than about 500 micron. In other embodiments, at least 90% of the flavor component particles are less than about 200 micron. In other embodiments, at least 90% of the flavor component particles are less than about 150 micron. In other embodiments, at least 90% of the flavor component particles are less than about 100 micron. In one embodiment, no more than about 10% of the flavor component particles are less than 10 micron and at least 90% of the flavor component particles are less than about 1000 micron. In one embodiment, no more than about 10% of the flavor component particles are less than 10 micron and at least 90% of the flavor component particles are less than about 200 micron.
  • the flavor component is menthol.
  • the flavor component may include tobacco, mint, fruit flavors, or food grade flavorings used in candy or baking. It should be appreciated that the flavor compound may be any flavoring compound known in the art, preferably a regulatory-approved flavoring compound.
  • the present invention includes a dry process or method of producing any one of the formulations described herein.
  • nicotine tartrate is dry milled.
  • nicotine is mixed with lactose.
  • the nicotine or nicotine salt is not bound to any other components of the formulation. That is, the formulation contains distinct particles of nicotine or a nicotine salt, and distinct particles of other components of the formulation, such as a sugar.
  • the nicotine is not bound to the lactose particles.
  • nicotine tartrate and lactose may be first dry mixed, such as in step 115 , and co-milled in step 125 .
  • the particles of the resulting formulation are filtered, such as with a sieve, to remove any particles larger than a threshold size value.
  • the particles of the resulting formulation are filtered again to remove any particles smaller than a threshold size value, resulting in the final dry powder formulation.
  • only one filtering step is needed.
  • two or more filtering steps are needed.
  • a cough suppressant component may be added to final formulation 150 .
  • Step 160 may contain any number of processing steps needed to obtain the desired particle size (e.g., 1-10 micron) for the cough suppressant component being added.
  • a cough suppressant component may be added to final formulation 150 .
  • Step 170 may contain any number of processing steps needed to obtain the desired particle size (e.g., 10-200 micron) for the cough suppressant component being added.
  • a flavor component may be added to final formulation 150 .
  • Step 180 may contain any number of processing steps needed to obtain the desired particle size (e.g., 10-1000 micron) for the flavor component being added.
  • the present invention also includes a wet process or method of producing any one of the formulations described herein.
  • nicotine tartrate is admixed with a carrier, such as lactose, to form a flowable mixture.
  • a carrier such as lactose
  • the mixture is atomized.
  • the mixture is dried, such as via a spray drier.
  • the process may optionally be performed via fluid bed drying, wherein nicotine tartrate can instead be spray dried onto the lactose.
  • the resulting nicotine particles are filtered, such as with a sieve, to remove any particles larger than a threshold size value.
  • the resulting nicotine particles are filtered again to remove any particles smaller than a threshold size value, resulting in the final dry powder formulation.
  • a cough suppressant component may be added to final formulation 260 .
  • Step 270 may contain any number of processing steps needed to obtain the desired particle size (e.g., 1-10 micron) for the cough suppressant component being added.
  • a cough suppressant component may be added to final formulation 260 .
  • Step 280 may contain any number of processing steps needed to obtain the desired particle size (e.g., 10-200 micron) for the cough suppressant component being added.
  • a flavor component may be added to final formulation 260 .
  • Step 290 may contain any number of processing steps needed to obtain the desired particle size (e.g., 10-1000 micron) for the flavor component being added.
  • the nicotine-based component may include nicotine and a pharmaceutical grade sugar prepared as solid discrete flowable particles, which may be entrained in the air inhaled by a subject so as to travel to the alveoli and smaller airways of the lungs. Further, the dried nicotine-sugar particles may be filtered, such as via one or more sieving steps, to isolate and segregate the desired particle sizes from those particles being removed.
  • initial particles of the nicotine-based component may be produced via the methods as described in U.S. Patent Application Publication No. 20120042886, which is incorporated by reference herein in its entirety.
  • nicotine and a pharmaceutical grade sugar, such as lactose can be mixed with a liquid carrier so as to form a flowable mixture.
  • any form of nicotine may be used as the nicotine-based component.
  • the form of nicotine used is one which achieves the fast uptake into the lungs of the patient.
  • the nicotine is blended with a sugar or other components.
  • the nicotine is a salt, which, at room temperature, is a solid.
  • the nicotine may further be a pharmacologically active analog or derivative of nicotine or substance that mimics the effect of nicotine, either alone or in combination with other active substances.
  • the nicotine may be added to a liquid carrier, such as water, and mixed to produce a generally homogeneous liquid mixture, which can then be dried by various method to form a dry particulate formulation.
  • a form of nicotine which is soluble in or miscible with a liquid carrier may also be used.
  • the nicotine may be a nicotine base, which, at room temperature, is a liquid that is miscible in water.
  • the nicotine base may be an oil formulation.
  • nicotine is present in the formulation as a free base.
  • the formulation may comprise a nicotine salt.
  • the nicotine salt is nicotine tartrate.
  • the nicotine salt is nicotine hydrogen tartrate.
  • the nicotine salt can be prepared from any suitably non-toxic acid, including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof.
  • inorganic acids examples include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, hexafluorophosphoric, citric, gluconic, benzoic, propionic, butyric, sulfosalicylic, maleic, lauric, malic, fumaric, succinic, tartaric, amsonic, pamoic, p-toluenenesulfonic, and mesylic.
  • Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, camphorsulfonic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, para-toluenesulfonic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic (besylate), stearic, sulfanilic, alginic, galacturonic, and the like.
  • the sugar is an inhalable sugar, and is generally solid at room temperature.
  • the sugar can be milled into a particulate formulation, either by itself, or co-milled with a nicotine component.
  • the sugar may also be soluble in a liquid carrier, such as water.
  • suitable sugars are lactose, sucrose, raffinose, trehalose, fructose, dextrose, glucose, maltose, mannitol, or combinations thereof.
  • the sugar is lactose.
  • the lactose is coarse lactose.
  • the sugar is alpha monohydrate lactose.
  • the sugar may be a natural or a synthetic sugar, and may include any analogs or derivatives of sugars. It should be appreciated that any form of sugar approved as an excipient may be used as a carrier in the production of the nicotine-based component. While not required, the sugar is preferably of a pharmaceutical grade as would be understood by those skilled in the art. Preferably, the pharmaceutical grade sugar used to be milled by itself, co-milled with a nicotine component or to create the flowable mixture is a non-spheronized sugar. The pharmaceutical grade sugar may be prepared in a non-spheronized form prior to dry or wet admixture with nicotine.
  • the pharmaceutical grade sugar may be first prepared in a non-spheronized form by freeze drying, milling, micronizing or the like.
  • the pharmaceutical grade sugar may be subjected to milling, bashing, grinding, crushing, cutting, sieving or other physical degradation process as understood by those skilled in the art, which ultimately reduces the particle size of the sugar and results in a non-spheronized sugar.
  • the formulation can further comprise any pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the subject such that it may perform its intended function.
  • the formulation is further comprised of a stabilizing agent.
  • a stabilizing agent Each material must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including nicotine, and not injurious to the subject.
  • Some materials that may useful in the formulation of the present invention include pharmaceutically acceptable carriers, for example sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter, lecithin, and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyr
  • compositions that can be useful in the formulation include any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of nicotine or any other compound useful within the invention, and are physiologically acceptable to the subject.
  • Supplementary active compounds including pharmaceutically acceptable salts of those compounds, may also be incorporated into the compositions.
  • Other additional ingredients that may be included in the compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, Pa.), which is incorporated herein by reference.
  • any method of blending particles in and for the methods and formulations of the present invention is contemplated here.
  • the blending can be conducted in one or more steps, in a continuous, batch, or semi-batch process.
  • two or more excipients are used, they can be blended together before, or at the same time as, being blended with the pharmaceutical agent microparticles.
  • the blending can be carried out using essentially any technique or device suitable for combining the microparticles with one or more other materials (e.g., excipients) effective to achieve uniformity of blend.
  • the blending process may be performed using a variety of blenders.
  • suitable blenders include V-blenders, slant-cone blenders, cube blenders, bin blenders, static continuous blenders, dynamic continuous blenders, orbital screw blenders, planetary blenders, Forberg blenders, horizontal double-arm blenders, horizontal high intensity mixers, vertical high intensity mixers, stirring vane mixers, twin cone mixers, drum mixers, and tumble blenders.
  • the blender preferably is of a strict sanitary design required for pharmaceutical products.
  • Tumble blenders are often preferred for batch operation.
  • blending is accomplished by aseptically combining two or more components (which can include both dry components and small portions of liquid components) in a suitable container.
  • a tumble blender is the TURBULATM, distributed by Glen Mills Inc., Clifton, N.J., USA, and made by Willy A. Bachofen AG, Maschinenfabrik, Basel, Switzerland.
  • the blender optionally may be provided with a rotary feeder, screw conveyor, or other feeder mechanism for controlled introduction of one or more of the dry powder components into the blender.
  • the milling step is used to fracture and/or deagglomerate the blended particles, to achieve a desired particle size and size distribution, as well as to enhance distribution of the particles within the blend.
  • Any method of milling can be used to form the particles of the invention, as understood by one of ordinary skill in the art.
  • a variety of milling processes and equipment known in the art may be used. Examples include hammer mills, ball mills, roller mills, disc grinders, jet milling and the like.
  • a dry milling process is used.
  • any liquid carrier may be used in the wet process.
  • the liquid carrier is one in which both the pharmaceutical grade sugar and the nicotine tartrate or the nicotine base are soluble.
  • the liquid carrier is water. While water is the preferred liquid carrier, other liquids in combination with or in place of water may be used.
  • the liquid carrier may comprise a mixture of an alcohol and water to form an azeotropic liquid carrier. If an alcohol is used, the alcohol is preferably a primary alcohol. In one embodiment, the alcohol is preferably a lower alkyl alcohol (i.e. C 1 to C 5 ), such as ethanol.
  • any ratio of water to alcohol may be used, and may be determined when balancing the solubility of the mixture components with the desired drying rate of the final mixture.
  • the ratio of alcohol to water in the liquid carrier may be from about 1:1 to 1:10, preferably from about 1:2 to 1:8 and more preferably from about 1:5 to 1:7 parts by weight.
  • the liquid carrier may be any liquid or liquids with which nicotine may be admixed with sugar to form a flowable mixture which is preferably of a generally uniform composition.
  • the percentage of nicotine in the formulation is between 1.5% and 20%. In one embodiment, the percentage of nicotine in the formulation is between 0.5% and 5%. In some embodiments, the percentage of nicotine in the formulation is between 1.5% and 2.5%. In other embodiments, the percentage of nicotine in the formulation is between 0.5% and 2.5%. In yet other embodiments the percentage of nicotine in the formulation is between 1.5% and 5%. In one embodiment, the percentage of nicotine in the formulation is about 2.5%. In another embodiment, the percentage of nicotine in the formulation is about 5%. In other embodiments the concentration of nicotine is between about 5-10%.
  • the percentage of nicotine in the formulation is about 10%.
  • the ratio of sugar to nicotine in the dry mixture or the wet flowable mixture may vary from about 1:100 to about 100:1, or from about 3:7 to about 3:2 or alternatively, from about 4:6 parts by weight.
  • the concentration of sugar in the dry mixture or the wet flowable mixture may vary from about 1 to about 10 w/v (g/100 ml), from about 2 to about 5 w/v (g/100 ml) or from about 3% w/v (g/100 ml).
  • the nicotine-sugar flowable mixture is dried, such as via a spray drier, to produce composite particles of nicotine-sugar that are suitable for delivery to the alveoli and lower airways of a subject.
  • a spray drier there is no limitation to the method of drying the flowable mixture. While a preferred method utilizes a spray drier, other drying techniques capable of producing appropriately sized particles may be used, such as fluidized bed drying.
  • the mixture is finely divided via passage through an orifice upon on entry to a spray dryer.
  • the flowable mixture may be passed through an atomizer, such as a rotary atomizer, to feed the flowable liquid into a spray dryer.
  • any rate of drying may be used (e.g., slow or rapid rate drying), provided such rate of drying results in the formation of dry particles of the desired size range.
  • the resultant particles formed via the spray drier may have a particle size from about 0.1 to about 5 micron.
  • a rotary atomizer may be operated at a liquid feed rate from about 2 to about 20 ml/min, or from 2 to about 10 ml/min, or from about 2 to about 5 ml/min. Further, the rotary atomizer may be operated from about 10,000 to about 30,000 rpm, from about 15,000 to about 25,000 rpm, or from about 20,000 to about 25,000 rpm.
  • particles of various sizes may be obtained by spray drying, and particles having the desired particle size may be more specifically selected when filtered, such as via one or more sieving steps, as described elsewhere herein.
  • the spray dryer may be operated at temperatures sufficiently high to cause the liquid carrier to rapidly evolve without raising the temperature of the sugar and nicotine within the mixture to a point at which these compounds begin to degrade. Accordingly, the spray dryer may be operated with an inlet temperature from about 120° C. to about 170° C., and an outlet temperature from about 70° C. to about 100° C.
  • the nicotine-based component particles may be spherical or of any other shape desired.
  • the particles may be produced with an uneven or a “dimpled” surface.
  • the uneven surface may produce a relative turbulence as the particles travel through the air, thus providing the particles with aerodynamic lift.
  • particles having such shape may be more readily entrained, and to remain entrained, in the air inhaled by a subject, thereby improving the ability of the nicotine-based component particles to travel to the alveoli and smaller airways.
  • the present invention includes formulations having components characterized by particular particle size ranges.
  • the formulations of the present invention can include nicotine-based particles sized substantially between about 1-10 microns, and preferably between about 2-5 microns.
  • the formulations can optionally include a cough suppressant component (such as menthol or mint) having particles in the size range of about 1-100 microns.
  • the formulations can optionally include a second cough suppressant component having particles in the size range of about 10-200 microns.
  • the formulations can include a flavor component (such as menthol or mint) having particles in the size range of about 10-1000 microns.
  • the particles of the present invention can be produced in relatively narrow size ranges via the use of at least one sieving step.
  • the sieving step includes using a sieve corresponding to the minimum or maximum of the desired particle size range to eliminate particles from the mixture that are smaller or bigger than the desired range.
  • a mixture of nicotine particles produced using the milling process described herein can be provided.
  • the mixture of nicotine particles will have a size distribution that is dependent on the milling conditions used and/or the characteristics of the input mixture to the mill.
  • the mixture of nicotine particles can first be passed through a 5 micron sieve, wherein substantially all of the particles smaller than 5 microns pass through the sieve and are collected.
  • the particles passing through the sieve can then transferred to a 1 micron sieve, wherein substantially all of the particles greater than 1 micron do not pass through the sieve.
  • the particles greater than 1 micron can be collected from the sieve, wherein the collected particles will be substantially sized in the range of 1-5 microns. Accordingly, such a process can be used to narrow the range of any mixture of particles to any of the desired particle size ranges as described hereinthroughout.
  • a mixture of particles can be provided that substantially meets either the minimum or maximum criteria of the desired particle size range. For example, if a nicotine particle size range of about 2-5 microns is desired, a mixture of nicotine particles can be provided wherein substantially all of the particles are less than 5 microns. Such a mixture can be produced by modifying the milling conditions, or when the particles are spray dried, by milling the spray dried material to result in a mixture of particles that are generally less than 5 microns. The mixture can then be transferred through a 2 micron sieve, wherein the particles not passing through the sieve are collected, and wherein the collected particles are substantially within the desired 2-3 micron range.
  • the percentage of particles falling within the desired particle size range for any of the components of the formulation of the present invention can be dependent on the technique used to produce that component. For example, if the targeted size of the nicotine component is in the range of 2-5 micron, it is understood that greater than 90% of that component will fall within the desired range when using a spray drying production technique on a relatively small scale. However, using a relatively large scale milling production technique may only yield greater than 70% of the nicotine component within such a targeted range.
  • the formulation may optionally include a cough suppressant component, wherein the particles of the cough suppressant component are sized between about 5 and 10 micron.
  • the particles of the cough suppressant component are sized between about 5 and 10 micron.
  • these non-respirable menthol or mint particles can reduce cough by soothing irritation in the subject's larger airways as well as the oro-pharynx.
  • the formulation of the present invention may optionally include a cough suppressant component having particles sized substantially between about 10-200 microns. This cough suppressant component may reduce a cough caused by irritation of the oro-pharynx, the glottis vocal cords and other anatomic regions more proximal or closer to the mouth that contain receptors that can trigger cough or trigger other unwanted sensations. As contemplated herein, these larger particles do not enter the sub-glottic airways because of their momentum.
  • the cough suppressant component of either the 5-10 or 10-200 micron ranges comprises menthol or mint. Further, it should be appreciated that any other cough suppressant compounds may be used instead of or in addition to menthol or mint, without limitation.
  • any form of menthol or mint such as a solid form of menthol or mint can be used for processing into menthol or mint particles useful within the present invention.
  • solid forms of menthol or mint include powders, crystals, solidified distillate, flakes, and pressed articles.
  • menthol or mint is in the form of crystals.
  • Menthol or mint can be processed into particles of a size ranging from about 5 ⁇ m to about 10 ⁇ m using any method known in the art.
  • menthol or mint is admixed with further liquid or solid additives for processing. Particulate additives can furthermore also be used.
  • menthol or mint is admixed with silicon dioxide.
  • menthol or mint is admixed with a sugar, such as lactose.
  • the menthol or mint is processed in a liquid carrier.
  • any liquid carrier may be used in the process of producing the menthol or mint particles.
  • the liquid carrier is water.
  • the liquid carrier is one in which the menthol or mint is soluble.
  • the liquid carrier may be any liquid or liquids with which menthol or mint, either alone or in combination with an additional component, forms a flowable mixture which is preferably of a generally uniform composition.
  • the menthol or mint flowable mixture may be dried, such as via a spray drier, to produce composite particles of menthol or mint, alone or in combination with an additional component, that are suitable for delivery to the alveoli and lower airways of a person.
  • a spray drier to produce composite particles of menthol or mint, alone or in combination with an additional component, that are suitable for delivery to the alveoli and lower airways of a person.
  • methods for drying the flowable mixture include, but are not limited to, spray drying, vacuum drying, and freeze drying.
  • any rate of drying may be used (e.g., slow or rapid rate drying), provided such rate of drying results in the formation of dry particles of the desired size range.
  • the formulation may optionally include a flavor component, wherein the particles of the flavor component are sized between about 10 and about 1000 micron.
  • the flavor component comprises menthol or mint and may be produced as previously described herein.
  • any known processing steps suitable for such compounds may be used to produce the flavoring component within the desired particle size range of about 10-1000 micron.
  • the relative weight percentage of each component in the formulation of the present invention can be varied to achieve different characteristics.
  • the relative weight percentages of the components can be modified for various reasons, for example, but not limited to: achieving a certain level of blood nicotine concentration while modulating the level of harshness on the airways of the subject, achieving a certain level of harshness while modulating the level of satisfaction perceived by the subject of the therapy, achieving better uptake of nicotine in the lungs of the patient, achieving faster blood nicotine kinetics, optimizing the cough suppressant performance of the formulation, varying or improving the taste of the formulation, and adjusting the relative dose of nicotine.
  • the formulation can be about 1-20% by weight flavor component, with a preferred weight of 1-5% flavor component. In certain embodiments, the formulation can be about 1-10 % by weight cough suppressant, with a preferred weight of 1-2.5% cough suppressant. In various embodiments, the remaining portion of the formulation, aside from any flavor components, cough suppressant components, carriers, or other components, is the nicotine component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
US14/856,116 2015-09-16 2015-09-16 System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations Abandoned US20170071248A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US14/856,116 US20170071248A1 (en) 2015-09-16 2015-09-16 System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
CN201510717020.5A CN106539122B (zh) 2015-09-16 2015-10-29 用于控制基于烟碱的干燥粉末制剂的粗糙感的系统和方法
KR1020187007522A KR102710989B1 (ko) 2015-09-16 2016-09-15 니코틴계 건조 분말 제형의 하시니스를 조절하기 위한 시스템 및 방법
MX2018003288A MX2018003288A (es) 2015-09-16 2016-09-15 Sistema y metodo para controlar la aspereza de las formulaciones en polvo seco basadas en nicotina.
RU2018113274A RU2707104C2 (ru) 2015-09-16 2016-09-15 Система и способ регулирования резкого привкуса сухих порошковых составов на основе никотина
PCT/US2016/051959 WO2017048970A1 (fr) 2015-09-16 2016-09-15 Système et procédé pour réguler l'âpreté de formulations de poudres sèches de nicotine
CA2998858A CA2998858A1 (fr) 2015-09-16 2016-09-15 Systeme et procede pour reguler l'aprete de formulations de poudres seches de nicotine
EP16847311.4A EP3349738A4 (fr) 2015-09-16 2016-09-15 Système et procédé pour réguler l'âpreté de formulations de poudres sèches de nicotine
JP2018514439A JP7021078B2 (ja) 2015-09-16 2016-09-15 ニコチンをベースとする乾燥粉末製剤のきつさを制御するためのシステムおよび方法
IL258138A IL258138A (en) 2015-09-16 2018-03-15 A system and method for controlling the hardness of nicotine-based dry powder compositions
US16/521,913 US11707432B2 (en) 2015-09-16 2019-07-25 System and method for controlling the harshness of nicotine-based dry powder formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/856,116 US20170071248A1 (en) 2015-09-16 2015-09-16 System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/521,913 Division US11707432B2 (en) 2015-09-16 2019-07-25 System and method for controlling the harshness of nicotine-based dry powder formulations

Publications (1)

Publication Number Publication Date
US20170071248A1 true US20170071248A1 (en) 2017-03-16

Family

ID=58256847

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/856,116 Abandoned US20170071248A1 (en) 2015-09-16 2015-09-16 System and Method for Controlling the Harshness of Nicotine-Based Dry Powder Formulations
US16/521,913 Active 2036-01-24 US11707432B2 (en) 2015-09-16 2019-07-25 System and method for controlling the harshness of nicotine-based dry powder formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/521,913 Active 2036-01-24 US11707432B2 (en) 2015-09-16 2019-07-25 System and method for controlling the harshness of nicotine-based dry powder formulations

Country Status (10)

Country Link
US (2) US20170071248A1 (fr)
EP (1) EP3349738A4 (fr)
JP (1) JP7021078B2 (fr)
KR (1) KR102710989B1 (fr)
CN (1) CN106539122B (fr)
CA (1) CA2998858A1 (fr)
IL (1) IL258138A (fr)
MX (1) MX2018003288A (fr)
RU (1) RU2707104C2 (fr)
WO (1) WO2017048970A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190001084A1 (en) * 2015-12-24 2019-01-03 Philip Morris Products S.A. Nicotine particle capsule
WO2019005889A1 (fr) * 2017-06-26 2019-01-03 Nude Nicotine, Inc. Sels de nicotine et procédés pour les préparer et les utiliser
CN111163651A (zh) * 2017-10-25 2020-05-15 菲利普莫里斯生产公司 具有边界元件的吸入器
JP2020521555A (ja) * 2017-05-31 2020-07-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粉末消耗品物品
US20210008307A1 (en) * 2018-03-26 2021-01-14 Philip Morris Products S.A. Ihaler with vortex capsule cavity

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9711771B2 (en) 2013-09-18 2017-07-18 Celgard, Llc Porous membranes filled with nano-particles, separators, batteries, and related methods
WO2024090892A1 (fr) * 2022-10-27 2024-05-02 주식회사 케이티앤지 Procédé de fabrication de poudre sèche de nicotine pour inhalation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186843A1 (en) * 2000-05-03 2003-10-02 Staniforth John Nicholas Powders for use in a dry powder inhaler
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US20080013839A1 (en) * 2006-07-14 2008-01-17 Fuji Xerox Co., Ltd. Decoding apparatus, decoding method, computer readable medium storing program thereof, and computer data signal
US20120042886A1 (en) * 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
US20140242174A1 (en) * 2011-09-06 2014-08-28 Verona Pharma Plc Treating cough and tussive attacks
US20140261474A1 (en) * 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
CA2146954C (fr) 1995-04-12 2008-06-17 Arthur Slutsky Inhalateur active par la respiration
CA2231968A1 (fr) * 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Methode de production d'un medicament a base de nicotine
CA2265198C (fr) 1998-03-11 2009-01-27 Zamel, Noe Methode d'obtention d'un medicament a base de nicotine et le medicament obtenu par cette methode
US6234169B1 (en) 1998-08-14 2001-05-22 Arthur Slutsky Inhaler
WO2001000654A2 (fr) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification et stabilisation de produits pharmaceutiques a base de peptides et de proteines
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
HUP0400161A2 (hu) 2001-06-08 2004-08-30 Vector Tobacco Ltd., Módosított nikotin- és nitrozamintartalmú dohány
US9339459B2 (en) * 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
AU2004228757A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
AU2007240986A1 (en) 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
WO2008069972A2 (fr) 2006-12-01 2008-06-12 Aradigm Corporation Systèmes destinés à mettre fin à l'usage du tabac
CN101583354A (zh) * 2006-12-01 2009-11-18 阿拉迪姆公司 用于终止烟草使用的系统
CA2682432C (fr) * 2007-03-30 2017-06-06 Duke University Dispositif et procede pour administrer un medicament
JP2011506589A (ja) * 2007-12-21 2011-03-03 ウェイ，エドワード，タク 気道疾患を治療するためのｐ−メンタン−３−カルボン酸エステル
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US8522769B2 (en) * 2010-08-18 2013-09-03 The Grill Company, Llc Folding worktable for use on an outdoor grill
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
WO2014012069A2 (fr) * 2012-07-12 2014-01-16 Mannkind Corporation Systèmes et procédés de libération de médicament en poudre sèche
US20140166027A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
JP6397493B2 (ja) * 2013-07-11 2018-09-26 アレックザ ファーマシューティカルズ， インコーポレイテッド メタ−サリチル酸とのニコチン塩
JP6672258B2 (ja) * 2014-04-08 2020-03-25 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン製剤及びその作製方法
ES2743898T3 (es) 2014-04-28 2020-02-21 Philip Morris Products Sa Inhalador de polvo nicotina
RU2680422C2 (ru) 2014-04-28 2019-02-21 Филип Моррис Продактс С.А. Ингалятор ароматизированного никотинового порошка

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120042886A1 (en) * 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US20030186843A1 (en) * 2000-05-03 2003-10-02 Staniforth John Nicholas Powders for use in a dry powder inhaler
US20080013839A1 (en) * 2006-07-14 2008-01-17 Fuji Xerox Co., Ltd. Decoding apparatus, decoding method, computer readable medium storing program thereof, and computer data signal
US20140242174A1 (en) * 2011-09-06 2014-08-28 Verona Pharma Plc Treating cough and tussive attacks
US20140261474A1 (en) * 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190001084A1 (en) * 2015-12-24 2019-01-03 Philip Morris Products S.A. Nicotine particle capsule
US10960152B2 (en) * 2015-12-24 2021-03-30 Philip Morris Products S.A. Nicotine particle capsule
JP2020521555A (ja) * 2017-05-31 2020-07-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粉末消耗品物品
US11458263B2 (en) * 2017-05-31 2022-10-04 Philip Morris Products, S.A. Nicotine powder consumable article
JP2023022212A (ja) * 2017-05-31 2023-02-14 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粉末消耗品物品
JP7352471B2 (ja) 2017-05-31 2023-09-28 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粉末消耗品物品
WO2019005889A1 (fr) * 2017-06-26 2019-01-03 Nude Nicotine, Inc. Sels de nicotine et procédés pour les préparer et les utiliser
CN111163651A (zh) * 2017-10-25 2020-05-15 菲利普莫里斯生产公司 具有边界元件的吸入器
US20210008307A1 (en) * 2018-03-26 2021-01-14 Philip Morris Products S.A. Ihaler with vortex capsule cavity
US11964099B2 (en) * 2018-03-26 2024-04-23 Philip Morris Products, S.A. Inhaler with vortex capsule cavity

Also Published As

Publication number Publication date
CN106539122B (zh) 2019-09-20
MX2018003288A (es) 2018-05-16
RU2707104C2 (ru) 2019-11-22
CN106539122A (zh) 2017-03-29
WO2017048970A1 (fr) 2017-03-23
US11707432B2 (en) 2023-07-25
EP3349738A4 (fr) 2019-06-19
EP3349738A1 (fr) 2018-07-25
RU2018113274A3 (fr) 2019-10-16
JP7021078B2 (ja) 2022-02-16
IL258138A (en) 2018-05-31
JP2018527385A (ja) 2018-09-20
US20190343178A1 (en) 2019-11-14
KR20180055818A (ko) 2018-05-25
RU2018113274A (ru) 2019-10-16
CA2998858A1 (fr) 2017-03-23
KR102710989B1 (ko) 2024-10-04

Similar Documents

Publication Publication Date Title
US11707432B2 (en) System and method for controlling the harshness of nicotine-based dry powder formulations
US9585835B1 (en) Inhalable nicotine formulations and methods of making and using the same
US20150283070A1 (en) Nicotine Formulations and Methods of Making the Same
KR102696600B1 (ko) 니코틴 제형, 및 이의 이용 및 제조방법
US10660883B2 (en) Inhalable nicotine formulations, and methods of making and using thereof
EP3592352A1 (fr) Formulations de nicotine à inhaler et procédés de production et d'utilisation de celles-ci
JP2024150531A (ja) 吸入可能なニコチン製剤、およびその作製および使用方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANSA CORPORATION (BARBADOS) INC., BARBADOS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HAN, STEVE;REEL/FRAME:044760/0850

Effective date: 20180126

Owner name: SANSA CORPORATION (BARBADOS) INC., BARBADOS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STENZLER, ALEX;REEL/FRAME:044760/0936

Effective date: 20180126

Owner name: SANSA CORPORATION (BARBADOS) INC., BARBADOS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELLIS, STEVEN;REEL/FRAME:044761/0033

Effective date: 20180126

Owner name: SANSA CORPORATION (BARBADOS) INC., BARBADOS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SLUTSKY, ARTHUR;REEL/FRAME:044760/0984

Effective date: 20180126

Owner name: SANSA CORPORATION (BARBADOS) INC., BARBADOS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZAMEL, NOE;REEL/FRAME:044761/0051

Effective date: 20180126

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NICO PUFF CORPORATION, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SANSA CORPORATION;REEL/FRAME:052353/0260

Effective date: 20180331

Owner name: PHILIP MORRIS PRODUCTS S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NICO PUFF CORPORATION;REEL/FRAME:052353/0382

Effective date: 20180131